By proceeding, you agree to our Terms of Use and Privacy Policy.
The 6th Targeted Protein Degradation Summit is the premier event for professionals in the field of protein degradation drug development. Returning to Boston in 2023, this summit has established itself as the longest-standing and most comprehensive gathering in the targeted protein degradation (TPD) space.As the trusted and definitive forum for the global network of protein degradation drug developers, the summit provides unparalleled industry insights that cover the entire spectrum of TPD, from early discovery all the way through clinical development and towards regulatory approval. It offers a unique opportunity for attendees to ensure their teams stay connected and remain at the forefront of this rapidly evolving field.With a focus on PROTAC and molecular glue clinical development, the summit goes beyond the basics and dives into next-generation strategies such as AbTACs, DUBTACs, bioPROTACs, ATACs, AUTOTACs, and more. By exploring these cutting-edge approaches, participants can gain invaluable knowledge, troubleshoot challenging problems, and find inspiration for new ideas through interactions with their peers.Attending the 6th Targeted Protein Degradation Summit will enable researchers, scientists, clinicians, and industry professionals to gain deep insights into the latest advancements, emerging trends, and key challenges in the field of protein degradation. Whether you are involved in drug discovery, preclinical research, clinical trials, or regulatory affairs, this summit is an essential platform to stay ahead of the curve and contribute to the development of novel therapeutics that harness the power of targeted protein degradation.Join us this fall in Boston to be part of this transformative event and shape the future of degrader therapeutics towards their first regulatory approvals. Don't miss the opportunity to connect with like-minded professionals, forge collaborations, and drive innovation in the exciting field of targeted protein degradation.
Learn the nuances of protein degradation and stay ahead in the rapidly evolving field.
Expand your knowledge of protein degradation mechanisms, target identification, and small molecule drug design to be updated on the trends and methodologies.
Share your research findings, and forge collaborations. Discover innovative technologies and tools in the exhibition area.
Be inspired by their scientific journeys and passion for advancing protein degradation. Witness groundbreaking discoveries and visions for the future.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tiss
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of pa
Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics.
HitGen is a rapidly growing biotech company with headquarters and the main research facility based in Chengdu, China and a subsidiary in the USA.
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
Right from the beginning, which is now more than fifty years ago, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task.
C4 Therapeutics (C4T) is a clinical-stage biotechnology company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives.
LifeSensors, Inc. is a biotechnology company leading the development of innovative research tools and services for the ubiquitin and ubiquitin-like protein pathways.
Nanome is a software company that is changing the way humanity understands and interacts with science. Using Virtual Reality our technology accelerates innovation and understanding in an intuitive manner.
NJ Biopharmaceuticals LLC (d/b/a NJ Bio) is a CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors.
Refeyn, the pioneer of mass photometry, is delivering a disruptive new generation of analytical instruments that let you weigh individual molecules with light.
The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented.
At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems.
Visualizing biomolecular structures through cryo-EM studies can provide insight into multiple stages of the drug development process, from target identification through formulation and manufacturing.
NEOsphere Biotechnologies is a pioneering proteomics company that creates value in strategic partnerships developing small molecule degraders as therapeutic agents against disease targets not yet exploited.
Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health.
BGI was founded in 1999 as a research organization to support the Human Genome Project.
Fida Biosystems offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al.
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics a
Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad,
Integrated Drug Discovery – from target to candidate. Our collaborative approach and closely aligned teams across all scientific disciplines means that we offer a truly integrated drug discovery solution. Operating from state-of-the-art research faci
Integrated Drug Discovery – from target to candidate. Our collaborative approach and closely aligned teams across all scientific disciplines means that we offer a truly integrated drug discovery solution. Operating from state-of-the-art research facilities in Loughborough we are a leading contract r
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.